The CONVERGE study evaluates NBTXR3's efficacy in stage III unresectable NSCLC with standard chemoradiation and durvalumab. NBTXR3, a hafnium oxide nanoparticle, is activated by radiotherapy to induce ...

It is hustling JDQ443 towards a phase 3 trial later this year that will compare the drug to docetaxel in patients with previously treated, locally advanced or metastatic KRAS G12C-mutated NSCLC ...

Suggested remit: To appraise the clinical and cost effectiveness of Durvalumab + chemoradiation within its marketing authorisation for treating oesophageal cancer (rare disease).

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered ...